NO20076022L - Peptider og peptidetterlignere for behandling av patologier kjennetegnet ved en inflammatorisk respons - Google Patents

Peptider og peptidetterlignere for behandling av patologier kjennetegnet ved en inflammatorisk respons

Info

Publication number: NO20076022L
Authority: NO; Norway
Prior art keywords: peptides; inflammatory response; treatment; pathologies characterized; peptide mimics
Prior art date: 2005-04-29

Application number

NO20076022A

Other languages

English (en)

Norwegian (no)

Inventor

Alan M Fogelman

Mohamad Navab

Original Assignee

Univ Alabama Res Forundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-29

Filing date

2007-11-22

Publication date

2008-01-28

2007-11-22 Application filed by Univ Alabama Res Forundation filed Critical Univ Alabama Res Forundation

2008-01-28 Publication of NO20076022L publication Critical patent/NO20076022L/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
230000028709 inflammatory response Effects 0.000 title abstract 2
230000007170 pathology Effects 0.000 title abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
102000003780 Clusterin Human genes 0.000 abstract 1
108090000197 Clusterin Proteins 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)

NO20076022A 2005-04-29 2007-11-22 Peptider og peptidetterlignere for behandling av patologier kjennetegnet ved en inflammatorisk respons NO20076022L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US67643105P	2005-04-29	2005-04-29
US69749505P	2005-07-07	2005-07-07
PCT/US2006/014839 WO2006118805A2 (en)	2005-04-29	2006-04-18	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

Publications (1)

Publication Number	Publication Date
NO20076022L true NO20076022L (no)	2008-01-28

Family

ID=37308461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20076022A NO20076022L (no)	2005-04-29	2007-11-22	Peptider og peptidetterlignere for behandling av patologier kjennetegnet ved en inflammatorisk respons

Country Status (17)

Country	Link
US (1)	US20100227825A1 (es)
EP (3)	EP2269623A1 (es)
JP (1)	JP2008539235A (es)
KR (1)	KR20080007491A (es)
AU (1)	AU2006242651B2 (es)
BR (1)	BRPI0610983A2 (es)
CA (1)	CA2607483A1 (es)
EA (2)	EA200900786A1 (es)
EC (1)	ECSP077829A (es)
IL (1)	IL186959A0 (es)
MA (1)	MA29488B1 (es)
MX (1)	MX2007013430A (es)
NO (1)	NO20076022L (es)
NZ (2)	NZ580954A (es)
SG (1)	SG173373A1 (es)
TN (1)	TNSN07396A1 (es)
WO (1)	WO2006118805A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7199102B2 (en)	2000-08-24	2007-04-03	The Regents Of The University Of California	Orally administered peptides synergize statin activity
US7723303B2 (en) *	2000-08-24	2010-05-25	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2012047930A2 (en)	2010-10-04	2012-04-12	The Regents Of The University Of California	Compositions and methods for treatment of gynecologic cancers
KR20070089996A (ko)	2004-12-06	2007-09-04	더 리전트 오브 더 유니버시티 오브 캘리포니아	세동맥의 구조 및 기능의 개선 방법
AU2007284801A1 (en)	2006-08-08	2008-02-21	The Regents Of The University Of Californina	Salicylanilides enhance oral delivery of therapeutic peptides
ES2540933T3 (es) *	2007-05-11	2015-07-14	Thomas Jefferson University	Métodos de tratamiento y prevención de enfermedades y trastornos neurodegenerativos
AU2014200542B2 (en) *	2007-05-11	2016-08-25	Rowan University	Methods of treatment and prevention of neurodegenerative diseases and disorders
AU2008296478B9 (en) *	2007-08-28	2015-03-19	The Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
US7985728B1 (en)	2007-09-20	2011-07-26	Abbott Cardiovascular Systems Inc.	Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en)	2007-09-20	2011-07-26	Abbott Cardiovascular Systems Inc.	Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en)	2007-09-20	2015-11-03	Abbott Cardiovascular Systems Inc.	Sustained release of Apo A-I mimetic peptides and methods of treatment
US8575107B2 (en)	2008-01-22	2013-11-05	Compugen Ltd.	Clusterin derived peptide
WO2010020822A1 (en) *	2008-08-19	2010-02-25	University Of Patras	Therapy for apolipoprotein-induced hypertriglyceridemia
WO2010049103A1 (en) *	2008-10-31	2010-05-06	Eth Zurich	Soluble truncated apom proteins and medical uses thereof
CN102753576A (zh) *	2009-09-30	2012-10-24	首尔大学教产学协力团	载脂蛋白a-1模拟肽以及包含其的用于治疗高血脂及高血脂相关疾病的治疗剂
US9241976B2 (en)	2011-08-29	2016-01-26	The Regents Of The University Of California	Use of HDL-related molecules to treat and prevent proinflammatory conditions
US9539300B2 (en)	2012-03-31	2017-01-10	The Regents Of The University Of California	Modulating disease through genetic engineering of plants
KR102017026B1 (ko) *	2013-01-10	2019-09-02	(주) 수파드엘릭사	염증 또는 알러지의 예방 또는 치료용 약학 조성물 및 염증 또는 알러지 개선용 화장료 조성물
AU2015298263B2 (en)	2014-07-31	2020-05-14	Anji Pharmaceuticals, Inc.	ApoE mimetic peptides and higher potency to clear plasma cholesterol
KR20170141692A (ko) *	2015-05-01	2017-12-26	알리스타 파마슈티컬즈, 인크.	안구 장애를 치료하기 위한 아디포넥틴 펩티드모방체
CN114181281A (zh) *	2015-05-12	2022-03-15	加利福尼亚大学董事会	用于炎症和纤维化的肽治疗
CA3008686C (en)	2015-12-18	2023-03-14	Talengen International Limited	Method for preventing and treating diabetic nephropathy
US10905736B2 (en)	2016-09-28	2021-02-02	The Regents Of The University Of California	Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism
US10426817B2 (en)	2017-01-24	2019-10-01	Macregen, Inc.	Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
CN111093687B (zh) *	2017-09-15	2024-07-09	凯恩塞恩斯株式会社	作为自身免疫疾病及骨病治疗剂的肽的用途
GB2576705A (en) *	2018-08-17	2020-03-04	E Miller Norman	Improvements in or relating to organic material
CA3138715A1 (en)	2019-06-14	2020-12-17	Zealand Pharma A/S	Pharmaceutical parenteral composition of dual glp1/2 agonist
CN111796098B (zh) *	2020-05-29	2021-06-01	中国科学院武汉病毒研究所	诊断新冠肺炎由重症转危重症的血浆蛋白标志物、检测试剂或检测工具

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US651842A (en) *	1899-08-18	1900-06-19	James Thomas Ford	Friction-clutch.
US3767040A (en)	1971-03-01	1973-10-23	Minnesota Mining & Mfg	Pressure-sensitive polyurethane adhesives
US4155913A (en) *	1973-02-08	1979-05-22	Hoffmann-La Roche Inc.	Thienotriazolodiazepine derivatives
NO812612L (no)	1980-08-06	1982-02-08	Ferring Pharma Ltd	Enzym-inhibitorer.
HU185263B (en) *	1981-06-12	1984-12-28	Richter Gedeon Vegyeszet	Process for producing peptides effective on the immuncontroll analogous with the tp5
CH661438A5 (it) *	1984-04-09	1987-07-31	Seuref Ag	Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
US4643988A (en)	1984-05-15	1987-02-17	Research Corporation	Amphipathic peptides
US4733665C2 (en)	1985-11-07	2002-01-29	Expandable Grafts Partnership	Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4969458A (en)	1987-07-06	1990-11-13	Medtronic, Inc.	Intracoronary stent and method of simultaneous angioplasty and stent implant
NZ229004A (en) *	1988-05-19	1993-09-27	Immunobiology Res Inst Inc	Tetrapeptides having t cell helper acitivity
US5480869A (en) *	1990-01-09	1996-01-02	The Regents Of The University Of California	Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
AU662885B2 (en) *	1990-06-07	1995-09-21	Scripps Research Institute, The	APO AI polypeptides, antibodies, and immunoassays
GB9022788D0 (en)	1990-10-19	1990-12-05	Cortecs Ltd	Pharmaceutical formulations
SE9103701D0 (sv)	1991-12-13	1991-12-13	Kabi Pharmacia Ab	Apolipoprotein
JPH07507554A (ja) *	1992-06-12	1995-08-24	エヌ・ブイ・イノゲネテイクス・エス・エイ	新規ペプチドおよびタンパク質，それらの調製方法，ならびにコレステロール受容体としてのそれらの使用
US5344822A (en) *	1992-08-12	1994-09-06	The Rogosin Institute	Methods useful in endotoxin prophylaxis and therapy
AU672028B2 (en) *	1992-08-14	1996-09-19	Shino-Test Corporation	Peptides containing respective amino acid sequences selected from among those of lipoprotein(a) and apolipoprotein(a), antibodies respectively recognizing these amino acid sequences, and method of assaying with these antibodies
EP0673387B1 (en) *	1992-12-11	1999-09-22	University Of Florida	Materials and methods for control of pests
US5721138A (en) *	1992-12-15	1998-02-24	Sandford University	Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
US6773719B2 (en)	1994-03-04	2004-08-10	Esperion Luv Development, Inc.	Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US5746223A (en)	1996-10-11	1998-05-05	Williams; Kevin Jon	Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US5635599A (en) *	1994-04-08	1997-06-03	The United States Of America As Represented By The Department Of Health And Human Services	Fusion proteins comprising circularly permuted ligands
US5595973A (en) *	1994-09-12	1997-01-21	Biomeasure Incorporated	Protection of hemopoietic cells during chemotherapy or radiotherapy
US5639726A (en)	1994-09-30	1997-06-17	The Regents Of The University Of Michigan	Peptide mediated enhancement of thrombolysis methods and compositions
SE9500778D0 (sv)	1995-03-03	1995-03-03	Pharmacia Ab	Process for producing a protein
US6717031B2 (en) *	1995-06-07	2004-04-06	Kate Dora Games	Method for selecting a transgenic mouse model of alzheimer's disease
US5912014A (en) *	1996-03-15	1999-06-15	Unigene Laboratories, Inc.	Oral salmon calcitonin pharmaceutical products
WO1997036927A1 (en)	1996-03-29	1997-10-09	Dario Boffelli	Amphipathic molecules as cholesterol and other lipid uptake inhibitors
SE9603068D0 (sv)	1996-08-23	1996-08-23	Pharmacia & Upjohn Ab	Process for purifying a protein
SE9603303D0 (sv)	1996-09-11	1996-09-11	Pharmacia & Upjohn Ab	Process for purifying a protein
US6555651B2 (en) *	1997-10-09	2003-04-29	The Trustees Of Columbia University In The City Of New York	Ligand binding site of rage and uses thereof
DK1493439T3 (da) *	1997-04-02	2012-01-30	Brigham & Womens Hospital	Middel til fastlæggelse af en persons risikoprofil for aterosklerotisk sygdom
US6696545B1 (en) *	1997-04-11	2004-02-24	Sangstat Medical Corporation	Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US6273913B1 (en) *	1997-04-18	2001-08-14	Cordis Corporation	Modified stent useful for delivery of drugs along stent strut
DE69805697T3 (de) *	1997-04-24	2006-11-30	Chemoxal S.A.	Desinfizierende und fungizide Zusammensetzung auf der Basis von Peressigsäure und einem Aminoxid
US6635623B1 (en) *	1997-06-13	2003-10-21	Baylor College Of Medicine	Lipoproteins as nucleic acid vectors
US6383808B1 (en) *	2000-09-11	2002-05-07	Isis Pharmaceuticals, Inc.	Antisense inhibition of clusterin expression
US6046166A (en) *	1997-09-29	2000-04-04	Jean-Louis Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en)	1997-09-29	2000-03-14	Jean-Louis Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) *	1997-09-29	1999-12-21	J. L. Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) *	1997-10-02	2001-09-11	Esperion Therapeutics, Inc.	Peptide/lipid complex formation by co-lyophilization
US6191151B1 (en) *	1997-11-12	2001-02-20	Howard M. Zik	Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers
US20030077641A1 (en) *	1998-03-11	2003-04-24	Laskowitz Daniel T.	Methods of suppressing microglial activation and systemic inflammatory responses
US6303619B1 (en) *	1998-03-12	2001-10-16	University Of Virginia	Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US6846636B1 (en) *	1998-05-15	2005-01-25	American National Red Cross	Methods and compositions for HDL holoparticle uptake receptor
US6019739A (en) *	1998-06-18	2000-02-01	Baxter International Inc.	Minimally invasive valve annulus sizer
US6228989B1 (en) *	1998-11-13	2001-05-08	The Regents Of The University Of California	Peptide substrates phosphorylated by P21-activated protein kinase
AU3116800A (en) *	1998-12-11	2000-06-26	Research Foundation Of The State University Of New York, The	Compositions and methods for altering cell migration
US7544772B2 (en) *	2001-06-26	2009-06-09	Biomarck Pharmaceuticals, Ltd.	Methods for regulating inflammatory mediators and peptides useful therein
MXPA01009893A (es)	1999-04-01	2003-07-28	Esperion Therapeutics Inc	Compuestos con eter, composiciones y usos de estos.
US6849714B1 (en) *	1999-05-17	2005-02-01	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) *	1999-09-10	2005-05-03	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
GB9911689D0 (en) *	1999-05-19	1999-07-21	Medical Res Council	Refolding method
US6727063B1 (en) *	1999-09-10	2004-04-27	Millennium Pharmaceuticals, Inc.	Single nucleotide polymorphisms in genes
JP2003513622A (ja) *	1999-11-02	2003-04-15	ヒューマンジノームサイエンシーズ，インコーポレイテッド	１９個のヒト分泌タンパク質
JP2001299364A (ja) *	1999-12-27	2001-10-30	Takeda Chem Ind Ltd	新規タンパク質およびそのｄｎａ
US6596544B1 (en)	2000-03-31	2003-07-22	The Regents Of The University Of California	Functional assay of high-density lipoprotein
US20030040505A1 (en)	2000-03-31	2003-02-27	The Regents Of The University Of California	Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
US6444681B1 (en) *	2000-06-09	2002-09-03	The Ohio State University Research Foundation	Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US6680203B2 (en)	2000-07-10	2004-01-20	Esperion Therapeutics, Inc.	Fourier transform mass spectrometry of complex biological samples
CA2415742A1 (en) *	2000-07-25	2002-01-31	Merck & Co., Inc.	N-substituted indoles useful in the treatment of diabetes
US6664230B1 (en)	2000-08-24	2003-12-16	The Regents Of The University Of California	Orally administered peptides to ameliorate atherosclerosis
US7723303B2 (en) *	2000-08-24	2010-05-25	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7166578B2 (en)	2000-08-24	2007-01-23	The Regents Of The University Of California	Orally administered peptides synergize statin activity
US7199102B2 (en) *	2000-08-24	2007-04-03	The Regents Of The University Of California	Orally administered peptides synergize statin activity
US7148197B2 (en)	2000-08-24	2006-12-12	The Regents Of The University Of California	Orally administered small peptides synergize statin activity
US7144862B2 (en) *	2000-08-24	2006-12-05	The Regents Of The University Of California	Orally administered peptides to ameliorate atherosclerosis
CN1962596A (zh)	2000-10-11	2007-05-16	埃斯佩里安医疗公司	用于控制胆固醇以及相关用途的酮化合物以及组合物
US20040122091A1 (en)	2000-10-11	2004-06-24	Esperion Therapeutics, Inc.	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
EP1363879A2 (en)	2000-10-11	2003-11-26	Esperion Therapeutics Inc.	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
AU2002211667A1 (en)	2000-10-11	2002-04-22	Esperion Therapeutics, Inc.	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
MXPA03003021A (es)	2000-10-11	2003-07-14	Esperion Therapeutics Inc	Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US6982348B2 (en) *	2001-01-26	2006-01-03	Takeda Pharmaceutical Company Limited	Aminoethanol derivatives
JP2002226457A (ja) *	2001-02-02	2002-08-14	Ajinomoto Co Inc	新規シスチン誘導体及び炎症因子活性化抑制剤
US6815426B2 (en) *	2001-02-16	2004-11-09	E. I. Du Pont De Nemours And Company	Angiogenesis-inhibitory tripeptides, compositions and their methods of use
US7217785B2 (en) *	2001-05-09	2007-05-15	The Regents Of The University Of California	Cysteine-containing peptides having antioxidant properties
CA2460787A1 (en)	2001-09-28	2003-04-03	Esperion Therapeutics, Inc.	Prevention and treatment of restenosis by local administration of drug
US20030125260A1 (en) *	2001-10-31	2003-07-03	Fortuna Haviv	Tetra-and pentapeptides having antiangiogenic activity
US7308303B2 (en) *	2001-11-01	2007-12-11	Advanced Bionics Corporation	Thrombolysis and chronic anticoagulation therapy
US20050154046A1 (en) *	2004-01-12	2005-07-14	Longgui Wang	Methods of treating an inflammatory-related disease
US7582670B2 (en) *	2001-12-13	2009-09-01	Natrogen Therapeutics, Inc.	Methods of treating an inflammatory-related disease
EP1497921A2 (en) *	2002-02-28	2005-01-19	Koninklijke Philips Electronics N.V.	Method for controlling the mode of an electronic application
US6930085B2 (en)	2002-04-05	2005-08-16	The Regents Of The University Of California	G-type peptides to ameliorate atherosclerosis
AR040603A1 (es) *	2002-07-19	2005-04-13	Abbott Lab S A	El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
JP2004067583A (ja) *	2002-08-06	2004-03-04	Sumitomo Pharmaceut Co Ltd	新規ペプチド誘導体
WO2004050037A2 (en) *	2002-12-04	2004-06-17	Agennix Incorporated	Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
WO2004069206A2 (en) *	2003-02-04	2004-08-19	University Of Connecticut Health Center	Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
US8088404B2 (en)	2003-03-20	2012-01-03	Medtronic Vasular, Inc.	Biocompatible controlled release coatings for medical devices and related methods
US20050070996A1 (en)	2003-04-08	2005-03-31	Dinh Thomas Q.	Drug-eluting stent for controlled drug delivery
US7291590B2 (en) *	2003-06-12	2007-11-06	Queen's University At Kingston	Compositions and methods for treating atherosclerosis
EP1506967B1 (en)	2003-08-13	2007-11-21	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
ES2381551T3 (es) *	2003-12-05	2012-05-29	The Cleveland Clinic Foundation	Marcadores de riesgo para enfermedad cardiovascular
JP5048486B2 (ja) *	2004-07-16	2012-10-17	トラスティーズオブタフツカレッジ	アポリポタンパク質ａ１の模倣物とその使用
CA2580501A1 (en) *	2004-09-16	2006-03-30	The Regents Of The University Of California	G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
KR20070089996A (ko) *	2004-12-06	2007-09-04	더 리전트 오브 더 유니버시티 오브 캘리포니아	세동맥의 구조 및 기능의 개선 방법
US20080293639A1 (en) *	2005-04-29	2008-11-27	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
MX2007014501A (es) *	2005-05-26	2008-02-07	Metabasis Therapeutics Inc	Tiromimeticos novedosos que contienen acido fosfinico.
US8101565B2 (en) *	2007-09-20	2012-01-24	Abbott Cardiovascular Systems Inc.	Sustained release of Apo A-I mimetic peptides and methods of treatment

2006
- 2006-04-18 MX MX2007013430A patent/MX2007013430A/es active IP Right Grant
- 2006-04-18 KR KR1020077027948A patent/KR20080007491A/ko not_active Ceased
- 2006-04-18 SG SG2011051224A patent/SG173373A1/en unknown
- 2006-04-18 BR BRPI0610983-7A patent/BRPI0610983A2/pt not_active Application Discontinuation
- 2006-04-18 NZ NZ580954A patent/NZ580954A/en not_active IP Right Cessation
- 2006-04-18 WO PCT/US2006/014839 patent/WO2006118805A2/en not_active Ceased
- 2006-04-18 EP EP10177858A patent/EP2269623A1/en not_active Withdrawn
- 2006-04-18 AU AU2006242651A patent/AU2006242651B2/en not_active Ceased
- 2006-04-18 EP EP06750791A patent/EP1890715A4/en not_active Withdrawn
- 2006-04-18 EP EP11155927.4A patent/EP2368561B1/en active Active
- 2006-04-18 CA CA002607483A patent/CA2607483A1/en not_active Abandoned
- 2006-04-18 JP JP2008508931A patent/JP2008539235A/ja active Pending
- 2006-04-18 NZ NZ563187A patent/NZ563187A/en not_active IP Right Cessation
- 2006-04-18 EA EA200900786A patent/EA200900786A1/ru unknown
- 2006-04-18 EA EA200702392A patent/EA012440B1/ru not_active IP Right Cessation
2007
- 2007-10-24 TN TNP2007000396A patent/TNSN07396A1/en unknown
- 2007-10-26 EC EC2007007829A patent/ECSP077829A/es unknown
- 2007-10-28 IL IL186959A patent/IL186959A0/en unknown
- 2007-11-22 NO NO20076022A patent/NO20076022L/no not_active Application Discontinuation
- 2007-11-27 MA MA30425A patent/MA29488B1/fr unknown
2010
- 2010-03-10 US US12/721,366 patent/US20100227825A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SG173373A1 (en)	2011-08-29
CA2607483A1 (en)	2006-11-09
EP2368561A1 (en)	2011-09-28
US20100227825A1 (en)	2010-09-09
MX2007013430A (es)	2008-03-19
AU2006242651B2 (en)	2013-05-16
ECSP077829A (es)	2008-02-20
EA200900786A1 (ru)	2009-10-30
WO2006118805A3 (en)	2007-06-07
NZ563187A (en)	2010-05-28
NZ580954A (en)	2011-05-27
JP2008539235A (ja)	2008-11-13
EP2368561B1 (en)	2013-12-04
MA29488B1 (fr)	2008-05-02
EP1890715A2 (en)	2008-02-27
TNSN07396A1 (en)	2009-03-17
WO2006118805A9 (en)	2007-01-18
IL186959A0 (en)	2008-02-09
EP1890715A4 (en)	2009-10-28
AU2006242651A1 (en)	2006-11-09
EA200702392A1 (ru)	2008-04-28
EA012440B1 (ru)	2009-10-30
BRPI0610983A2 (pt)	2010-08-10
WO2006118805A2 (en)	2006-11-09
EP2269623A1 (en)	2011-01-05
KR20080007491A (ko)	2008-01-21

Legal Events

Date	Code	Title	Description
2020-05-04	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20076022L (no)	2008-01-28	Peptider og peptidetterlignere for behandling av patologier kjennetegnet ved en inflammatorisk respons
Morciano et al.	2020	Mitophagy in cardiovascular diseases
WO2009100348A3 (en)	2009-10-22	Peptides and peptide mimetics to treat pathologies associated with eye disease
Urbina-Varela et al.	2020	Impact of mitophagy and mitochondrial unfolded protein response as new adaptive mechanisms underlying old pathologies: sarcopenia and non-alcoholic fatty liver disease
Imai et al.	2008	The discovery of angiotensin‐converting enzyme 2 and its role in acute lung injury in mice
CL2012000063A1 (es)	2012-08-24	Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
EP1496930A4 (en)	2006-06-21	G-TYPE PEPTIDES FOR IMPROVING ATHEROSCLEROSIS
NO20083187L (no)	2008-09-19	Anvendelse av DHA, EPA eller DHA-avledet EPA til behandling av patologi assosiert med cellulaer oksidativ skade
NO20075542L (no)	2007-11-01	Sammensetning for rensing av ioneimplantert fotoresist i innledende del av produksjonslinjer
Man et al.	2022	Endothelial nitric oxide synthase in the perivascular adipose tissue
EA200801776A1 (ru)	2009-02-27	Гидразиды миндальной кислоты
ES2498822T3 (es)	2014-09-25	Partículas poliméricas sensibles a la temperatura en aplicaciones de separación de proteínas
Uberti et al.	2023	A combination of α-lipoic acid (ALA) and palmitoylethanolamide (PEA) blocks endotoxin-induced oxidative stress and cytokine storm: a possible intervention for COVID-19
NO20083780L (no)	2008-11-03	Topisk sammensetning omfattende en antibakteriell substans
NO20082240L (no)	2008-07-22	GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
Iciek et al.	2022	Reactive sulfur compounds in the fight against COVID-19
Rysz et al.	2021	Oxidative stress-related susceptibility to aneurysm in Marfan’s syndrome
NO341676B1 (no)	2017-12-18	Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI
CR20130287A (es)	2013-10-07	Tableta oralmente desintegradora
Yu et al.	2023	Respiratory infection and inflammation in cystic fibrosis: a dynamic interplay among the host, microbes, and environment for the ages
Gorini et al.	2021	H2S as a bridge linking inflammation, oxidative stress and endothelial biology: a possible defense in the fight against SARS-CoV-2 infection?
Qin et al.	2022	Lipid droplets and their participation in Zika virus infection
Kinger et al.	2023	Molecular chaperones’ potential against defective proteostasis of amyotrophic lateral sclerosis
Wang et al.	2021	Role of histone deacetylases in bone development and skeletal disorders
Miyazaki	2023	Calpain and cardiometabolic diseases